Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma-Reference-Cited by-同舟云学术

Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma

Published:2022-07-22 Issue:29 Volume:8 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Vaughan Hannah J.¹²^ORCID,Zamboni Camila G.¹²^ORCID,Hassan Laboni F.¹²^ORCID,Radant Nicholas P.¹²,Jacob Desmond³,Mease Ronnie C.³,Minn Il¹³^ORCID,Tzeng Stephany Y.¹²^ORCID,Gabrielson Kathleen L.⁴,Bhardwaj Pranshu¹²^ORCID,Guo Xin⁴,Francisco David¹²^ORCID,Pomper Martin G.¹³⁵^ORCID,Green Jordan J.¹²⁵⁶^ORCID

Affiliation:

1. Department of Biomedical Engineering and the Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

2. Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

3. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA.

4. Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

5. Department of Materials Science and Engineering and the Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21231, USA.

6. Departments of Neurosurgery, Oncology, Ophthalmology, and Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Abstract

Hepatocellular carcinoma (HCC) develops predominantly in the inflammatory environment of a cirrhotic liver caused by hepatitis, toxin exposure, or chronic liver disease. A targeted therapeutic approach is required to enable cancer killing without causing toxicity and liver failure. Poly(beta-amino-ester) (PBAE) nanoparticles (NPs) were used to deliver a completely CpG-free plasmid harboring mutant herpes simplex virus type 1 sr39 thymidine kinase (sr39) DNA to human HCC cells. Transfection with sr39 enables cancer cell killing with the prodrug ganciclovir and accumulation of 9-(4-18F-fluoro-3-hydroxymethylbutyl)guanine (18F-FHBG) for in vivo imaging. Targeting was achieved using a CpG-free human alpha fetoprotein (AFP) promoter (CpGf-AFP-sr39). Expression was restricted to AFP-producing HCC cells, enabling selective transfection of orthotopic HCC xenografts. CpGf-AFP-sr39 NP treatment resulted in 62% reduced tumor size, and therapeutic gene expression was detectable by positron emission tomography (PET). This systemic nanomedicine achieved tumor-specific delivery, therapy, and imaging, representing a promising platform for targeted treatment of HCC.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference65 articles.

1. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities

2. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis

3. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean?

4. Focus on hepatocellular carcinoma

5. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomimetic nanocomplexes orchestrate post-stroke cerebral microenvironment via microglia-targeted siRNA delivery;Nano Today;2024-10

2. Advances in polymer-centric nanomedicines for theranostic cancer treatment;Journal of Drug Delivery Science and Technology;2024-10

3. Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment;Biomedicines;2024-08-16

4. Combinatorial Synthesis of Alkyl Chain‐Capped Poly(β‐Amino Ester)s for Effective siRNA Delivery;Macromolecular Bioscience;2024-07-25

5. Emerging nanomedicine strategies for hepatocellular carcinoma therapy;iMetaOmics;2024-07-04